USRE39384E1 - Substituted thiazolidinedione derivatives - Google Patents

Substituted thiazolidinedione derivatives Download PDF

Info

Publication number
USRE39384E1
USRE39384E1 US10/389,381 US38938103A USRE39384E US RE39384 E1 USRE39384 E1 US RE39384E1 US 38938103 A US38938103 A US 38938103A US RE39384 E USRE39384 E US RE39384E
Authority
US
United States
Prior art keywords
alkyl
pharmaceutical composition
formula
composition according
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US10/389,381
Inventor
Philip Christopher Buxton
Donald Colin Mackenzie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/GB1993/001853 external-priority patent/WO1994005659A1/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to US10/389,381 priority Critical patent/USRE39384E1/en
Application granted granted Critical
Publication of USRE39384E1 publication Critical patent/USRE39384E1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • test compounds in the above mentioned tests may be carried out using conventional methods, generally chromatographic methods such as high pressure liquid chromatography.
  • the active ingredient may be administered by mouth usually once or twice a day and in an amount in the range of from about 0.025 mg/kg to 25 mg/kg, for example 0.1 mg/kg to 20 mg/kg. Similar dosage regimens are suitable for the treatment and/or prophylaxis of hyperlipidaemic hyperlipidaemia in non-human mammals.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A compound of formula (I):
Figure USRE039384-20061107-C00001
or a tautomeric form thereof, wherein:
  • R1 represents a hydrogen atom, C1-12 alkyl, C1-12 alkoxy, C1-12 alkylcarbonyl or arylC1-12 alkyl;
  • A1 represents hydrogen or 1 to 4 optional substituents selected from the group consisting of: C1-12 alkyl, C1-12 alkoxy, aryl, and halogen; aryl represents phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C1-12 alkyl, phenyl, C1-12 alkoxy, haloC1-12 alkyl, hydroxy, nitro, C1-12 alkoxycarbonyl, C1-12 alkoxycarbonyl C1-12 alkyl, C1-12 alkoxycarbonyloxy, or C1-12 alkylcarbonyl:
  • A2 represents a benzene ring having 1 to 3 optional substituents selected from hydrogen, halogen, C1-12 alkyl, C1-12 alkoxy; and
  • M− represents a counter-ion other than the maleate ion.

Description

This is a continuation of Ser. No. 08/464,990, filed Jun. 5, 1995, now abandoned, which is a continuation of Ser. No. 08/392,878, filed Mar. 3, 1995, which is a §371 of PCT/GB93/01853 filed Sep. 1, 1993.
This invention relates to certain novel compounds, to a process for preparing such compounds, to pharmaceutical compositions containing such compounds and to the use of such compounds and compositions in medicine.
European Patent Application, Publication Number 0,30628 relates to certain thiazolidinedione derivatives disclosed as having hypoglycemic and hypolipidaemic activity.
It is now surprisingly indicate indicated that a specific group of compounds from within formula (I) of EP-A-0,306,228 have improved selectivity of action and are therefore of particular use in the treatment of Type II diabetes. These compounds are also indicated to be of particular use for the treatment and/or prophylaxis of other diseases including hyperlipidaemia, hypertension and cardiovascular disease, especially atherosclerosis. In addition these compounds are considered to be useful for treating certain eating disorders, in particular the regulation of appetite and food intake in subjects suffering from disorders associated with under-eating, such as anorexia nervous nervousa, and disorders associated with over-eating, such as obesity and anorexia bulimia.
These compounds show good aqueous stability and good stability in the solid form, certain of these compounds are indicated to be particularly stable. In addition these compounds are significantly more soluble in water than the corresponding free base.
The surprising and advantageous stability and aqueous solubility of these, compounds provides for significant formulation and bulk handling advantages.
Accordingly, the present invention provides a compound of formula (1):
Figure USRE039384-20061107-C00002
or a tautomeric form thereof and/or a pharmaceutically acceptable solvate thereof, wherein:
    • R1 represents a hydrogen atom, an alkyl group, a acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group, A1 represents hydrogen or 1 to 4 optional substituents selected from the group consisting of alkyl, alkoxy, aryl and halogen or A1 represents two substituents on adjacent carbon atoms, which substituents together with the carbon atoms to which they are attached form a substituted or unsubstituted aryl group; A2 represents a benzene ring having 1 to 3 optional substituents; and M− represents a counter-ion.
Suitable counter-ions M− include-ions include ions provided by pharmaceutically acceptable acids.
A suitable source of counter-ions M− is provided by those pharmaceutically acceptable acids having a pKa in the range of from 0.1 to 4.5 and especially in the range of from 175 1.75 to 2.5.
Favoured pharmaceutically acceptable acids include mineral acids, such as hydrobromic, hydrochloric, and sulphuric acids, and organic acids, such as methanesulphonic, tartaric and malcic maleic acids, especially tartaric and malcic maleic acid.
A preferred counter-ion is the maleate-ion HOOC.CH═CH.COO−.
Preferably, A1 is hydrogen.
Suitable optional substituents for the moiety A2 include up to three substituents selected from halogen, substituted or unsubstituted alkyl or alkoxy.
Favourably, A2 represents a moiety of formula (e):
Figure USRE039384-20061107-C00003
wherein R2 and R3 each independently represent hydrogen, halogen, substituted or unsubstituted akyl or alkoxy.
Suitably, R2 and R3 each independently represent hydrogen, halogen, alkyl or alkoxy.
Preferably, R2 and R3 each represent hydrogen.
Suitably, R1 represents hydrogen, alkyl, acyl, especially acetyl, or benzyl.
Preferably, R1 represents an alkyl group, for example a methyl group.
Preferably the moiety:
Figure USRE039384-20061107-C00004
in formula (I) is a moiety of formula:
Figure USRE039384-20061107-C00005
wherein A1 and R1 are as defined above
A preferred compound of formula (I) is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt.
The compounds of formula (I) are salts. The present invention extends to all forms of such salts including those provided by association of the salting hydrogen with all possible salt forming parts of the molecule and especially that provided by association with the pyridin nitrogen.
As indicated above a compound of formula (I) may exist in one of several tantomeric forms, all of which are encompassed by the present invention. It will be appreciated that the present invention encompasses all of the isomeric forms of the compounds of formula (I) and the pharmaceutically acceptable salts thereof, including any stereoisomeric forms thereof, whether as individual isomers or as mixtures of isomers.
When used herein the term ‘aylr’ ‘aryl’ includes phenyl and naphthyl optionally substituted with up to five, preferably up to three, groups selected from halogen, alkyl, phenyl, alkoxy, haloalkyl, hydroxy, nitro, alkoxycarbonyl, aloxycarbonylalkyl, alkylcarbonyloxy, or alkylcarbonyl groups.
When used herein the term ‘halogen’ refers to fluorine, chlorine, bromine and iodine; preferably chlorine.
Suitable alkyl groups, including alkyl groups per se and alkyl groups that form part of other groups such as alkoxy groups, are C1-12 groups having straight or branched carbon chains, especially C1-6 alkyl groups e.g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl or tert-butyl groups.
Suitable substituents for any alkyl group include those indicated above in relation to the term “aryl”.
Suitable acyl groups include alkylcarbonyl groups.
Suitable pharmaceutically acceptable solvates include hydrates.
In a further aspect the present invention also provides a process for the preparation of a compound of formula (I), or a tautomeric form thereof, and/or a pharmaceutically acceptable solvate thereof, which process comprises reacting a compound of formula (II):
Figure USRE039384-20061107-C00006
wherein R1. A1 and A2 are as defined in relation to formula (I) with a source of above defined counter-ion M−; and thereafter if required preparing a pharmaceutically acceptable solvate thereof.
A suitable source of a counter-ion M− is a pharmaceutically acceptable acid.
A suitable source of counter-ions includes pharmaceutically acceptable acids having a pKa in the range of from 1.5 to 4.5; especially in the range of from 1.75 to 2.5.
Favoured pharmaceutically acceptable acids include mineral acids, such as hydrobromic, hydrochloric and sulphuric acids, and organic acids, such as methanesulphonic, tartaric and maleic acids.
A preferred source of a counter-ion is maleic acid.
The reaction between the compound of formula (I) and the source of counter-ion M− is generally carried out under conventional salt forming conditions, for example by admixing the compound of formula (I) and the source of counter-ion M−, suitably in approximately equimolar amounts but preferably using a slight excess of the source of counter-ion M−, in a solvent, generally a C1-4 alkanolic solvent such as ethanol, at any temperature which provides a suitable rate of formation of the required product, generally at an elevated temperature for example at the reflux temperature of the solvent and thereafter crystallising the required product.
Pharmaceutically acceptable solvates of the compound of formula (I) may be prepared using conventional chemical procedures.
The compound of formula (II) may be prepared according to methods disclosed in EP-A-0306228.
Suitable sources of counter-ion are known commercially available sources, such as malcic maleic acid, or the required source may be prepared according to known procedures.
Where appropriate the isomeric forms of the compounds of formula (I) and the pharmaceutically acceptable salts thereof may be prepared as individual isomers using conventional chemical procedures.
The stability of the compounds of the invention may be determined using conventional quantitative analytical methods: For example the stability of the compounds in the solid form may be determined by using accelerated stability test such as differential scanning calorimetry (I) (DSC), thermogravimetric analysis (TGA) and isothermal testing at elevated temperatures including conventional storage test wherein the test compounds are stored under controlled conditions of temperature and humidity over known periods of time. Quantitative analysis of the test compounds, against appropriate reference standards before, during and after the storage period allows the stability of the test compound to be determined.
As stated the compounds of the invention are significantly more soluble in water than the corresponding free base. Thus a convenient method for determing determining the stability of the compounds of the invention in aqueous solution involves determining the degree of precipitation of the parent free base from an aqueous solution of the test compound at known conditions of temperature and over known periods of time. We have found that the compounds of formula (I) show good aqueous stability. In particular the compounds of formula (I) wherein M− represents maleate or tarrate tartrate are particularly stable in aqueous solution. Most surprisingly, the compounds of formula (I) wherein M− represents a maleate-ion, HOOC.CH═CH.COO−, were found to be particularly stable in aqueous solution.
The quantitative analysis of the test compounds in the above mentioned tests may be carried out using conventional methods, generally chromatographic methods such as high pressure liquid chromatography.
As mentioned above the compounds of the invention are indicated as having useful therapeutic properties:
The present invention accordingly provides a compound of formula (I), and/or a pharmaceutically acceptable solvate thereof. , for use as an active therapeutic substance.
Thus the present invention provides a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment of and/or prophylaxis of hyperglycaemia.
In a further aspect the present invention also provides compound of formula (I). , or a tautomeric form thereof and/or a pharmaceutically acceptable solvate thereof, for use in the treatment and/or prophylaxis of hyperlipidaemia.
As indicated hereinbefore the present invention also provides a compound of formula (I) or a tautomeric form thereof and/or a pharmaceutically acceptable solvate thereof for use in the treatment of hypertension, cardiovascular disease and certain eating disorders.
Cardiovascular disease includes in particular atherosclerosis.
Certain eating disorders include in particular the regulation of appetite and food intake in, subjects suffering from disorders associated with under-eating, such as anorexia nervosa and disorders associated with over-eating, such as obesity and anorexia bulimia.
A compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable solvate thereof, may be administered per se or, preferably as a pharmaceutically composition also comprising a pharmaceutically acceptable carrier.
Accordingly, the present invention also provides a pharmaceutical composition comprising a compound of formula (I), or a tautomeric form thereof, a pharmaceutically acceptable solvate thereof, and a pharmaceutically acceptable carrier therefor.
As used herein the term ‘pharmaceutically acceptable‘ ’ embraces compounds, compositions and ingredients for both human and veterinary use: for example the term ‘pharmaceutically acceptable salt’ embraces a veterinarily acceptable salt.
The composition may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
Usually the pharmaceutical compositions of the present invention will be adapted for oral administration, although compositions for administration by other routes, such as by injection and percutaneous absorption are also envisaged.
Particularly suitable compositions for oral administration are unit dosage forms such as tablets and capsules. Other fixed unit dosage forms, such as powders presented in sachets, may also be used.
In accordance with conventional pharmaceutical practice the carrier may comprise a diluent, filler, disintegrant, wetting agent, lubricant, colourant flavourant or other conventional adjuvant.
Typical carriers include, for example, microcrystalline cellulose, starch, sodium starch glycollate. , polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium, stearate or sodium lauryl sulphate.
Most suitably the composition will be formulated in unit dose form. Such unit dose will normally contain an amount of the active ingredient in the range of from 0.1 to 1000 mg, more usually 0.1 to 500 mg, and more especially 0.1 to 250 mg.
The , present invention further provides a method for the treatment and/or prophylaxis of hyperglycaemia in a human or non-human mammal which comprises administering an effective, non-toxic, amount of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable solvate thereof to a hyperglycaemia hyperglycemic human or non-human mammal in need thereof.
The present invention further provides a method for the treatment of hyperlipidaemia in a human or non-human mammal, which comprises administering an effective, non toxic, amount of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable solvate thereof, to a hyperlipidaemic human or non-human mammal in need thereof.
Conveniently, the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
In the treatment and/or prophylaxis of hyperglycaemic humans, and/or the treatment and/or prophylaxis of hyperlipidaemic human, the compound of formula (I), or a tautomeric form, thereof and/or a pharmaceutically acceptable solvate thereof, may be taken in doses, such as those described above, one in six times a day in a manner such that the total daily dose for a 70 kg adult will generally be in the range of from 0.1 to 6000 mg, and more usually about 1 to 1500 mg.
In the treatment and/or prophylaxis of hyperglycaemic non human mammals, especially dogs, the active ingredient may be administered by mouth usually once or twice a day and in an amount in the range of from about 0.025 mg/kg to 25 mg/kg, for example 0.1 mg/kg to 20 mg/kg. Similar dosage regimens are suitable for the treatment and/or prophylaxis of hyperlipidaemic hyperlipidaemia in non-human mammals.
The dosages regimens for the treatment or of hypertension cardiovascular disease and eating disorders will generally be those mentioned above in relation to hyperglycaemia.
In a further aspect the present invention provides the use of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperglycaemia.
The present invention also provides the use of a compound of formula (I), or a tautomeric form thereof and/or a pharmaceutically acceptable solvate thereof, for the manufacture of a medicament for the treatment and/or prophylaxis of hyperlipidaemia, hypertension, cardiovascular disease or certain eating disorders.
The following Example illustrates the invention but does not limit it in any way.
EXAMPLE 1
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4 dione (470 g) and maleic acid (137 g) were dissolved in ethanol (41) at boiling. The hot solution was filtered via diatomaceous earth and was then allowed to cool slowly with gentle agitation. After leaving in a refrigerator at 0-5° C. for several hours, the maleate salt was filtered off, washed with ethanol and dried in vacuo at 50° C. to give 446 g (73%) of product, m.p 120-121° C.
1H NMR δ (d6-DMSO): 3.0-3.35 (2H, complex); 3.10 (3H, s); 3.95 (2H, t); 4.15 (2H, t); 4.85 (1H, complex): 6.20 (2H, s); 6.65 (1H, t); 6.85 (3H, complex); 7.15 (2H, d) 7.65 (1H, t); 8.05 (1H, complex); 11.85-12.1 (1H, broad, exchanges with D2O)
A very broad signal was observed in the range 2-5 ppm which is thought to be due to residual water from the solvent and the exchangeable carboxylic acid protons.
EXAMPLE2 EXAMPLE 2
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt
5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt (294.6 g, 0.825 M) and maleic acid (95.8 g 0.825 m) were stirred in refluxing ethanol (2.71) until all the solid had dissolved. Decolourising charcoal was added and the hot solution filtered through celite, allowed to cool to room temperature with stirring. After cooling in a refrigerator at 0-5° C. for several hours, the title compound was filtered, collected and dried at 50° C. under vacuum overnight to give 364.1 g (87%) of product, m.p. 119-119.5° C.
The 1H NMR spectra was as for Example 1.

Claims (13)

1. A compound of formula (I):
Figure USRE039384-20061107-C00007
or a tautomeric form thereof, wherein:
R1 represents a hydrogen atom, C1-12 alkyl, C1-12 alkoxy, C1-12 alkylcarbonyl or arylC1-12 alkyl;
A1 represents hydrogen or 1 to 4 optional substituents selected from the group consisting of: C1-12 alkyl, C1-12 alkoxy, aryl and halogen;
aryl represents phenyl or naphthyl optionally substituted with up to five groups selected from halogen, C1-12 alkyl, phenyl, C1-12 alkoxy, haloC1-12 alkyl, hydroxy, nitro, C1-12 alkoxycarbonyl, C1-12 alkoxycarbonyl, C1-12 alkoxycarbonyloxy, or C1-12 alkylcarbonyl;
A2 represents a benzene ring having 1 to 3 optional substituents selected from hydrogen, halogen, C1-12 alkyl, C1-12 alkoxy; and
M− represents a counter-ion other than the maleate ion
which is 5-[4 -[2 -(N-methyl-N-( 2 -pyridyl)amino)ethoxy]benzyl]thiazolidine- 2,4 -dione tartaric acid salt or a tautomer of 5 -[ 4 -[2 -(N-methyl-N-( 2 -pyridyl)amino)ethoxy]benzyl]thiazolidine- 2,4 -dione tartaric acid salt.
2. A process for the preparation of a compound of formula (I) according to claim 1, or a tautomeric form thereof, which process comprises reacting a compound of formula (II):
Figure USRE039384-20061107-C00008
wherein R1, A1, and A2 are as defined in relation to formula (I) in claim 1, with a source of counter-ion M− which is defined in relation to formula (I), as defined in claim 1
5-[4 -[2 -(N-methyl-N-( 2 -pyridyl)amino)ethoxy]benzyl]thiazolidine- 2,4 -dione or a tautomeric form thereof with a source of tartarate ion.
3. The compound according to claim 1, wherein the salt is in a solid form.
4. A pharmaceutical composition comprising a compound according to claim 1 and at least one pharmaceutically acceptable carrier.
5. The pharmaceutical composition according to claim 4 comprising an individual isomer of 5-[4 -[2 -(N-methyl-N-( 2 -pyridyl)amino)ethoxy]benzyl]thiazolidine- 2,4 -dione tartaric acid salt or a tautomer of 5 -[ 4 -[2 -(N-methyl-N-( 2 -pyridyl)amino)ethoxy]benzyl]thiazolidine- 2,4 -dione tartaric acid salt.
6. The pharmaceutical composition according to claim 4 comprising a mixture of isomers of 5-[4 -[2 -(N-methyl-N-( 2 -pyridyl)amino)ethoxy]benzyl]hiazolidine- 2,4 -dione tartaric acid salt or a tautomer of 5 -[4 -[ 2 -(N-methyl-N-( 2 -pyridyl)amino)ethoxy]benzyl]thiazolidine- 2,4 -dione tartaric acid salt.
7. The pharmaceutical composition according to any one of claims 4 to 6, wherein the composition is in a form suitable for oral administration.
8. The pharmaceutical composition according to claim 7, wherein the form is chosen from tablets, capsules, and powders.
9. The pharmaceutical composition according to claim 7, wherein the form is a tablet.
10. The pharmaceutical composition according to claim 4, wherein the composition is in a form suitable for injection.
11. The pharmaceutical composition according to claim 4, wherein the composition is in a form suitable for percutaneous absorption.
12. The pharmaceutical composition according to claim 4, wherein the at least one pharmaceutically acceptable carrier is chosen from microcrystalline cellulose, starch, sodium starch glycollate, polyvinylpyrrolidone, polyvinylpolypyrrolidone, magnesium stearate, and sodium lauryl sulphate.
13. The pharmaceutical composition according to claim 4, wherein the at least one pharmaceutically acceptable carrier comprises a diluent, filler, disintegrant, wetting agent, lubricant, colourant, flavourant, or adjuvant.
US10/389,381 1993-09-01 2003-03-17 Substituted thiazolidinedione derivatives Expired - Lifetime USRE39384E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/389,381 USRE39384E1 (en) 1993-09-01 2003-03-17 Substituted thiazolidinedione derivatives

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/GB1993/001853 WO1994005659A1 (en) 1992-09-05 1993-09-01 Substituted thiazolidinedione derivatives
US39287895A 1995-03-03 1995-03-03
US46499095A 1995-06-05 1995-06-05
US08/892,045 US5910592A (en) 1992-09-05 1997-07-14 Substituted thiazolidinedione derivatives
US10/389,381 USRE39384E1 (en) 1993-09-01 2003-03-17 Substituted thiazolidinedione derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/892,045 Reissue US5910592A (en) 1992-09-05 1997-07-14 Substituted thiazolidinedione derivatives

Publications (1)

Publication Number Publication Date
USRE39384E1 true USRE39384E1 (en) 2006-11-07

Family

ID=37301374

Family Applications (1)

Application Number Title Priority Date Filing Date
US10/389,381 Expired - Lifetime USRE39384E1 (en) 1993-09-01 2003-03-17 Substituted thiazolidinedione derivatives

Country Status (1)

Country Link
US (1) USRE39384E1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes

Citations (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0008203A1 (en) 1978-08-04 1980-02-20 Takeda Chemical Industries, Ltd. Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
US4197297A (en) * 1976-11-17 1980-04-08 Smithkline Corporation 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines
GB2082584A (en) 1980-08-27 1982-03-10 Glaxo Group Ltd Tetrazole derivatives
US4376777A (en) 1980-01-07 1983-03-15 Takeda Chemical Industries, Ltd. Thiazolidine derivatives use
US4572912A (en) 1983-08-30 1986-02-25 Sankyo Company Limited Thiazolidine derivatives, their preparation and compositions containing them
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
EP0193256A1 (en) 1985-01-19 1986-09-03 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
EP0207581A2 (en) 1985-02-26 1987-01-07 Sankyo Company Limited Thiazolidine derivatives, their preparation and use
US4725610A (en) 1984-10-03 1988-02-16 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
EP0306228A1 (en) 1987-09-04 1989-03-08 Beecham Group Plc Substituted thiazolidinedione derivatives
US4873255A (en) 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
US4879303A (en) 1986-04-04 1989-11-07 Pfizer Inc. Pharmaceutically acceptable salts
EP0419035A1 (en) 1989-08-25 1991-03-27 Beecham Group Plc Thiazolidine dione derivatives
US5039687A (en) * 1985-12-04 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamine compounds having enhancing activity
US5232925A (en) 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US5478852A (en) 1993-09-15 1995-12-26 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5521201A (en) 1987-09-04 1996-05-28 Beecham Group P.L.C. Method for treatment of atherosclerosis
US5726055A (en) 1991-11-19 1998-03-10 Smithkline Beecham Plc Process for the preparation of pharmaceutically active thiazolidine compounds by a yeast reductase
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
WO2001094343A1 (en) 2000-06-08 2001-12-13 Smithkline Beecham P.L.C. 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
WO2001094344A1 (en) 2000-06-08 2001-12-13 Smithkline Beecham P.L.C. Thiazolidinedione salt for treatment of diabetes mellitus
WO2002012233A1 (en) 2000-08-04 2002-02-14 Smithkline Beecham Plc Tartrate salts of thiazolidinedione derivative
WO2002012234A1 (en) 2000-08-04 2002-02-14 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
WO2002012232A1 (en) 2000-08-04 2002-02-14 Smithkline Beecham P.L.C. Tartrate salt of thiazolidinedione derivative
WO2002012231A1 (en) 2000-08-04 2002-02-14 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
WO2002020517A1 (en) 2000-09-07 2002-03-14 Smithkline Beecham P.L.C. A thiazolidinedione derivative and its use as antidiabetic
WO2002020518A1 (en) 2000-09-05 2002-03-14 Smithkline Beecham P.L.C. Thiazolidinone nitrate salt
WO2002020520A1 (en) 2000-09-05 2002-03-14 Smithkline Beecham P.L.C. A thiazolidinedione derivative and its use as antidiabetic
WO2002020519A1 (en) 2000-09-06 2002-03-14 Smithkline Beecham P.L.C. The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20020050563A1 (en) 1991-11-19 2002-05-02 Smithkline Beecham P.L.C. Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
WO2002051839A1 (en) 2000-12-22 2002-07-04 Smithkline Beecham P.L.C. 5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt
US20020099081A1 (en) 1997-12-16 2002-07-25 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US20020133016A1 (en) 1997-12-16 2002-09-19 Smithkline Beecham P.L.C. Substituted thiazolidined derivative, process for its preparation and its pharmaceutical use
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical

Patent Citations (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4197297A (en) * 1976-11-17 1980-04-08 Smithkline Corporation 6-Halo-7,8-dihydroxy-1-(hydroxyphenyl)-2,3,4,5-tetrahydro-1H-3-benzazepines
EP0008203A1 (en) 1978-08-04 1980-02-20 Takeda Chemical Industries, Ltd. Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
US4287200A (en) 1978-08-04 1981-09-01 Takeda Chemical Industries, Ltd. Thiazolidine derivatives
US4340605A (en) 1978-08-04 1982-07-20 Takeda Chemical Industries, Ltd. Thiazolidine derivatives
US4438141A (en) 1978-08-04 1984-03-20 Takeda Chemical Industries, Ltd. Thiazolidine derivatives
US4444779A (en) 1978-08-04 1984-04-24 Takeda Chemical Industries, Ltd. Thiazolidine derivatives
US4376777A (en) 1980-01-07 1983-03-15 Takeda Chemical Industries, Ltd. Thiazolidine derivatives use
GB2082584A (en) 1980-08-27 1982-03-10 Glaxo Group Ltd Tetrazole derivatives
US4572912A (en) 1983-08-30 1986-02-25 Sankyo Company Limited Thiazolidine derivatives, their preparation and compositions containing them
US4582839A (en) 1984-03-21 1986-04-15 Takeda Chemical Industries, Ltd. 2,4-thiazolidinediones
US4725610A (en) 1984-10-03 1988-02-16 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
EP0193256A1 (en) 1985-01-19 1986-09-03 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, their production and use
US4687777A (en) 1985-01-19 1987-08-18 Takeda Chemical Industries, Ltd. Thiazolidinedione derivatives, useful as antidiabetic agents
EP0207581A2 (en) 1985-02-26 1987-01-07 Sankyo Company Limited Thiazolidine derivatives, their preparation and use
US5039687A (en) * 1985-12-04 1991-08-13 Hoechst-Roussel Pharmaceuticals Inc. N-(pyrrol-1-yl)pyridinamine compounds having enhancing activity
US4879303A (en) 1986-04-04 1989-11-07 Pfizer Inc. Pharmaceutically acceptable salts
US4873255A (en) 1987-02-04 1989-10-10 Sankyo Company Limited Thiazolidinone derivatives, their preparation and their use
US5232925A (en) 1987-09-04 1993-08-03 Beecham Group P.L.C. Compounds
US6288095B1 (en) 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5002953A (en) * 1987-09-04 1991-03-26 Beecham Group P.L.C. Novel compounds
EP0306228A1 (en) 1987-09-04 1989-03-08 Beecham Group Plc Substituted thiazolidinedione derivatives
US5521201A (en) 1987-09-04 1996-05-28 Beecham Group P.L.C. Method for treatment of atherosclerosis
EP0419035A1 (en) 1989-08-25 1991-03-27 Beecham Group Plc Thiazolidine dione derivatives
US5726055A (en) 1991-11-19 1998-03-10 Smithkline Beecham Plc Process for the preparation of pharmaceutically active thiazolidine compounds by a yeast reductase
US20020050563A1 (en) 1991-11-19 2002-05-02 Smithkline Beecham P.L.C. Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
US20020106762A1 (en) 1991-11-19 2002-08-08 Smith Kline Beecham Plc Process for the preparation of pharmaceutically active thiazolidine or oxazolidine compounds by a yeast reductase
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
US5478852A (en) 1993-09-15 1995-12-26 Sankyo Company, Limited Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US5478852C1 (en) 1993-09-15 2001-03-13 Sankyo Co Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus
US20020137940A1 (en) 1997-12-16 2002-09-26 Smithkline Beecham P.L.C. 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical
US20020133016A1 (en) 1997-12-16 2002-09-19 Smithkline Beecham P.L.C. Substituted thiazolidined derivative, process for its preparation and its pharmaceutical use
US20020099081A1 (en) 1997-12-16 2002-07-25 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
WO2001094343A1 (en) 2000-06-08 2001-12-13 Smithkline Beecham P.L.C. 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
WO2001094344A1 (en) 2000-06-08 2001-12-13 Smithkline Beecham P.L.C. Thiazolidinedione salt for treatment of diabetes mellitus
WO2002012234A1 (en) 2000-08-04 2002-02-14 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
WO2002012231A1 (en) 2000-08-04 2002-02-14 Smithkline Beecham P.L.C. Tartrate salts of thiazolidinedione derivative
WO2002012232A1 (en) 2000-08-04 2002-02-14 Smithkline Beecham P.L.C. Tartrate salt of thiazolidinedione derivative
WO2002012233A1 (en) 2000-08-04 2002-02-14 Smithkline Beecham Plc Tartrate salts of thiazolidinedione derivative
WO2002020520A1 (en) 2000-09-05 2002-03-14 Smithkline Beecham P.L.C. A thiazolidinedione derivative and its use as antidiabetic
WO2002020518A1 (en) 2000-09-05 2002-03-14 Smithkline Beecham P.L.C. Thiazolidinone nitrate salt
WO2002020519A1 (en) 2000-09-06 2002-03-14 Smithkline Beecham P.L.C. The hydrochloride salt of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
WO2002020517A1 (en) 2000-09-07 2002-03-14 Smithkline Beecham P.L.C. A thiazolidinedione derivative and its use as antidiabetic
WO2002051839A1 (en) 2000-12-22 2002-07-04 Smithkline Beecham P.L.C. 5-'4-'2-(n-methyl-n- (2-pyridyl)amino)ethoxy!benzyl!thiazolidine-2, 4-dione mesylate salt

Non-Patent Citations (23)

* Cited by examiner, † Cited by third party
Title
Baba, S., et al., "New Antidiabetic Agent ADD-3878", 31 (Suppl 2), 77A (1982).
Berge et al., "Review Article: Pharmaceutical Salts", Journal of Pharmaceutical Sciences, 66(1): 1-16 (1977).
Chang, A.Ay., et al., "Ciglitazone, a New Hypoglycemic Agent II. Effect on Glucose and Lipid Metabolisms and Insulin Binding in the Adipose Tissue of C57BL/6J-ob/ob and -+/? Mice", Diabetes, 32, 839-845 (1983).
Chang, A.Y., et al., "Ciglitazone, a New Hypoglycemic Agent 3, Effect on Glucose Disposal and Gluconeogenesis in Vivo in C57BL/6J-Ob/Ob and -+/? Mice", Diabetologia, 25, 514-(1983).
Fujita et al., Reduction of Insulin Resistance in Obese And/Or Diabetic Animals By 5-[4-(1-Methylcyclohexylmethoxy)Benzyl]-Thiazolidine-2,4-Dione (ADD-3878, U-63,287, Ciglitazone), A New Antidiabetic Agent, 32(9) Diabetes 804-10 (Sep. 1983).
Ganong, W.F., Review of Medical Physiology, Lange Medical Publications 272 (1983).
L.E. Bottiger, Ed., Carlson et al., "Pronounced Lowering of Serum Levels of Lipoprotein Lp(a) in Hyperlipidaemic Subjects Treated with Nicotinic Acid", Journal of Internal Medicine, 226(4): 271-76 (1989).
Mohrbacher, R.J., et al., "Pharmacologic Intervention in Diabetes Mellitus", Annual Reports in Medicinal Chemistry, 22, 213-222 (1987).
Silverman, R.B., "Identification of the Active Part: The Pharmacophore, The Organic Chemistry of Drug Design and Drug Action", Academic Press, pp. 11-13 (1992).
Sohda et al., "Studies on Antidiabetic Agents, II. Synthesis of 5-[4-(1-methylcyclohexylmethoxy)-benzyl]-thiazolidine-2,4-dione (ADD-3878) and its Derivatives", Chemical and Pharmaceutical Bulletin, 30(10): 3580-3600 (1982).
Sohda et al., Studies on Antidiabetic Agents. II. Synthesis of 5-[4-(1-Methylcyclohexylmethoxy)-Benzyl]Thiazolidine-2,4-Dione (ADD-3878 And Its Derivatives, 10 Chem Pharm Bull. (Tokyo) 3580-600 (Oct. 30, 1982).
Sohda, T. et al., "Studies on Antidiabetic Agents. I. Synthesis of 5-[4-(2-Methyl-2-phenylpropoxy)-benzyl]-thiazolidine 2,4-dione (AL-321) and Related Compounds", Chem. Pharm. Bull., 30(10), 3563-3573 (1982).
Sohda, T., et al., "A New Antidiabetic Agent, AD-4833, and Structure-Activity Relationships of 5-[4-(Pyridylalkoxy)benzyl]-2,4-thiazolidinediones", J. Pharm. Sci., 76(11), S173 (1987).
Sohda, T., et al., "Studies on Antidiabetic Agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy)benzyl]-2,4-thiazolidinediones", Arzneimittel Forschung, 40(1), 37-42 (1990).
U.S. Appl. No. 10/019,355, filed Apr. 19, 2000, Blackler et al.
U.S. Appl. No. 10/030,323, filed Apr. 19, 2000, Blackler et al.
U.S. Appl. No. 10/030,875, filed Apr. 19, 2000, Blackler et al.
U.S. Appl. No. 10/030,877, filed Apr. 19, 2000, Blackler et al.
U.S. Appl. No. 10/048,123, filed Apr. 19, 2000, Blackler et al.
U.S. Appl. No. 10/221,686, filed Mar. 14, 2001, Craig.
USP Dictionary, p. 694 (2002).
USP Dictionary, p. 911 (2002).
Wilson and Grisvold's Textbook of Organic Medicine and Pharmaceutical Chemistry, pp. 590-592 8<SUP>th </SUP>Ed. 1982.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013082106A1 (en) 2011-12-02 2013-06-06 The General Hospital Corporation Differentiation into brown adipocytes

Similar Documents

Publication Publication Date Title
US5910592A (en) Substituted thiazolidinedione derivatives
US5741803A (en) Substituted thiazolidinedionle derivatives
US5391565A (en) Oxazolidine dione derivatives
US5132317A (en) Compounds
EP0419035B1 (en) Thiazolidine dione derivatives
WO1994013650A1 (en) Heterocyclic derivatives and their use in pharmaceuticals
EP0555251A1 (en) Thiazolidine dione derivatives
EP0356214A2 (en) Thiazolidine dione derivatives
EP0555264A1 (en) Novel compounds
US5063240A (en) Novel compounds
EP0635007A1 (en) Heterocyclic compounds and their use in the treatment of type ii-diabetes
EP0555249A1 (en) Thiazolidinedione derivatives
USRE39384E1 (en) Substituted thiazolidinedione derivatives
WO1994029302A1 (en) Heterocyclic derivatives and their use in pharmaceuticals
US5589492A (en) Heterocyclic compounds and their use in the treatment of Type-II diabetes

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

SULP Surcharge for late payment

Year of fee payment: 7

FPAY Fee payment

Year of fee payment: 12